Clinical Trials Browser

Phase 1/2 × FED × pembrolizumab × Clear all

NCT05467748 2026-01-27

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms